Top Markets
#1 TENDIES TENDIES +22.61%
#2 Helium Helium +19.02%
#3 Pons Pons +18.16%
#4 Songbird Songbird +14.57%
#5 Biconomy Biconomy +11.78%
#6 Seeker Seeker +10.69%
#7 MarsCoin MarsCoin +9.79%
#8 OSK OSK +9.75%
#9 pipedog pipedog +9.28%
#10 Lista DAO Lista DAO +7.33%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
SpyGlass Pharma, Inc. Common Stock SpyGlass Pharma, Inc. Common Stock

SpyGlass Pharma, Inc. Common Stock

SGP
Rank in Stocks #10213
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to... SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Share Price
$26.13
Last synced: 2026-08-28
Market Cap
$873.45M
Change (1 day)
-2.99%
Change (1 year)
-
Country
US
Trade SpyGlass Pharma, Inc. Common Stock (SGP)

Category

Healthcare
Revenue for SpyGlass Pharma, Inc. Common Stock (SGP)
Revenue in Aug 2026 TTM: 0
According to SpyGlass Pharma, Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for SpyGlass Pharma, Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH